In a report released today, Evan Seigerman from BMO Capital reiterated a Buy rating on Structure Therapeutics, Inc. Sponsored ADR, with a price target of $100.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Evan Seigerman has given his Buy rating due to a combination of factors that highlight the potential of Structure Therapeutics, Inc.’s oral GLP-1 receptor agonist, aleniglipron, in the obesity market. The upcoming results from the ACCESS and ACCESS II trials are anticipated to demonstrate significant weight loss efficacy, particularly with the 120mg dosage, which is expected to be competitive with existing treatments like orforglipron.
The scarcity of effective oral small molecule GLP-1 receptor agonists and the use of the Chugai scaffold, which has been validated by orforglipron, add value to aleniglipron. Despite being behind competitors in the timeline, the early-stage nature of the oral GLP-1 obesity market presents a substantial opportunity for growth. Additionally, while there are short-term pricing pressures due to U.S. government agreements, the long-term growth potential remains strong, supporting the Outperform rating and a target price of $100 per share.
In another report released on November 13, Cantor Fitzgerald also maintained a Buy rating on the stock with a $65.00 price target.